Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Johnson and Johnson
Merck
McKinsey
Baxter

Last Updated: August 15, 2022

qinlock Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Qinlock patents expire, and when can generic versions of Qinlock launch?

Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. There are seven patents protecting this drug.

This drug has forty patent family members in twelve countries.

The generic ingredient in QINLOCK is ripretinib. Additional details are available on the ripretinib profile page.

DrugPatentWatch® Generic Entry Outlook for Qinlock

Qinlock will be eligible for patent challenges on May 15, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 30, 2040. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for qinlock
International Patents:40
US Patents:7
Applicants:1
NDAs:1
Clinical Trials: 1
What excipients (inactive ingredients) are in qinlock?qinlock excipients list
DailyMed Link:qinlock at DailyMed
Drug patent expirations by year for qinlock
DrugPatentWatch® Estimated Generic Entry Opportunity Date for qinlock
Generic Entry Date for qinlock*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for qinlock

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Deciphera Pharmaceuticals LLCPhase 1

See all qinlock clinical trials

US Patents and Regulatory Information for qinlock

qinlock is protected by seven US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of qinlock is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting qinlock

Methods of treating gastrointestinal stromal tumors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB

Amorphous kinase inhibitor formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods of treating gastrointestinal stromal tumors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMER-PLANTER ERYTHRODYSESTHESIA SYNDROME

Methods of treating gastrointestinal stromal tumors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM HYPERTENSION

Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR

FDA Regulatory Exclusivity protecting qinlock

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE RECEIVED PRIOR TREATMENT WITH 3 OR MORE KINASE INHIBITORS, INCLUDING IMATINIB
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for qinlock

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Deciphera Pharmaceuticals (Netherlands) B.V. Qinlock ripretinib EMEA/H/C/005614
Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Authorised no no yes 2021-11-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for qinlock

When does loss-of-exclusivity occur for qinlock?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Taiwan

Patent: 2136257
Estimated Expiration: See Plans and Pricing

Patent: 2136258
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering qinlock around the world.

Country Patent Number Title Estimated Expiration
Japan 2010503701 See Plans and Pricing
Australia 2007296450 Kinase inhibitors useful for the treatment of proliferative diseases See Plans and Pricing
South Korea 20110074633 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Dow
Harvard Business School
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.